XFOR Logo

X4 Pharmaceuticals, Inc. (XFOR) 

NASDAQ
Market Cap
$98.45M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
772 of 776
Rank in Industry
431 of 433

Largest Insider Buys in Sector

XFOR Stock Price History Chart

XFOR Stock Performance

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström …

Insider Activity of X4 Pharmaceuticals, Inc.

Over the last 12 months, insiders at X4 Pharmaceuticals, Inc. have bought $0 and sold $536,941 worth of X4 Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at X4 Pharmaceuticals, Inc. have bought $29,875 and sold $645,594 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 25,000 shares for transaction amount of $29,875 was made by WYZGA MICHAEL S (director) on 2023‑08‑18.

List of Insider Buy and Sell Transactions, X4 Pharmaceuticals, Inc.

2024-10-15SalePresident and CEO
31,897
0.0161%
$0.56$17,926-6.79%
2024-10-07SalePresident and CEO
239,436
0.1183%
$0.55$131,522-1.74%
2024-10-07SaleChief Operating Officer
67,695
0.0345%
$0.57$38,329-1.74%
2024-10-07SaleChief Scientific Officer
76,920
0.0389%
$0.56$43,306-1.74%
2024-10-07SaleChief Commercial Officer
11,127
0.0059%
$0.58$6,506-1.74%
2024-10-07SaleChief Financial Officer
230,645
0.1141%
$0.55$126,901-1.74%
2024-09-09SaleChief Operating Officer
2,642
0.0016%
$0.66$1,738-16.09%
2024-03-11SalePresident and CEO
49,678
0.0287%
$0.88$43,856-1.16%
2024-03-11SaleChief Operating Officer
15,409
0.0089%
$0.88$13,591-1.16%
2024-03-11SaleChief Scientific Officer
14,235
0.0082%
$0.88$12,552-1.16%
2024-03-11SaleChief Financial Officer
52,500
0.0304%
$0.88$46,347-1.16%
2024-02-12SalePresident and CEO
21,695
0.0129%
$1.01$21,892-9.72%
2024-02-12SaleChief Operating Officer
3,683
0.0022%
$1.01$3,709-9.72%
2024-02-12SaleChief Scientific Officer
787
0.0005%
$1.01$793-9.72%
2024-02-12SaleChief Financial Officer
27,721
0.0165%
$1.01$27,973-9.72%
2023-11-03SalePresident and CEO
39,906
0.0231%
$0.90$35,915-11.18%
2023-11-01SalePresident and CEO
199,531
0.1172%
$0.73$145,658+11.79%
2023-11-01SaleChief Operating Officer
67,695
0.0398%
$0.73$49,417+11.79%
2023-11-01SaleChief Scientific Officer
67,695
0.0398%
$0.73$49,417+11.79%
2023-11-01SaleChief Financial Officer
230,645
0.1355%
$0.73$168,371+11.79%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bain Capital Life Sciences Investors Llc$23.51M10.0716.92M0%+$01.89
Nea Management Company Llc$20.83M8.9214.99M0%+$00.1
BlackRock$12.14M5.28.74M+3.78%+$442,496.77<0.0001
The Vanguard Group$10.88M4.667.83M-2.26%-$251,781.81<0.0001
OrbiMed$9.92M4.257.13M0%+$00.08
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.